Phase2 Prospective, Multi-center, Open-label, Controlled Trial to Assess the Safety and Efficacy of Cellular Immunotherapy with MDR-103 for Induction of Mixed Chimerism and Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kid

Awarded By

Contributors

Start/End

  • December 11, 2018 - October 31, 2023